Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
135.42
+0.46 (0.34%)
Dec 20, 2024, 4:00 PM EST - Market closed
Neurocrine Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 349.1 | 251.1 | 262.9 | 340.8 | 187.1 | 112.3 | Upgrade
|
Short-Term Investments | 878.9 | 780.5 | 726.4 | 370.5 | 613.9 | 558.2 | Upgrade
|
Cash & Short-Term Investments | 1,228 | 1,032 | 989.3 | 711.3 | 801 | 670.5 | Upgrade
|
Cash Growth | 12.14% | 4.28% | 39.08% | -11.20% | 19.46% | 3.01% | Upgrade
|
Receivables | 481.1 | 439.3 | 350 | 185.5 | 157.1 | 126.6 | Upgrade
|
Inventory | 45.8 | 38.3 | 35.1 | 30.5 | 28 | 17.3 | Upgrade
|
Other Current Assets | 121.7 | 97.8 | 79.1 | 45.5 | 30.1 | 16.6 | Upgrade
|
Total Current Assets | 1,877 | 1,607 | 1,454 | 972.8 | 1,016 | 831 | Upgrade
|
Property, Plant & Equipment | 337.3 | 347.3 | 145.6 | 155.8 | 127.4 | 116.2 | Upgrade
|
Long-Term Investments | 770.6 | 849.4 | 401.5 | 624.4 | 265.3 | 355.6 | Upgrade
|
Goodwill | 6.1 | 5.8 | 5.4 | - | - | - | Upgrade
|
Other Intangible Assets | 34.5 | 35.5 | 37.2 | - | - | - | Upgrade
|
Long-Term Deferred Tax Assets | 454.4 | 362.6 | 305.9 | 315.1 | 319.4 | - | Upgrade
|
Other Long-Term Assets | 55.5 | 43.8 | 19.6 | 4.4 | 6.4 | 3.2 | Upgrade
|
Total Assets | 3,535 | 3,251 | 2,369 | 2,073 | 1,735 | 1,306 | Upgrade
|
Accounts Payable | 95.7 | 108.9 | 67.3 | 51.5 | 39.4 | 41.4 | Upgrade
|
Accrued Expenses | 297 | 315.5 | 271.3 | 111.6 | 94.7 | 69.3 | Upgrade
|
Current Portion of Long-Term Debt | - | 170.1 | 169.4 | - | - | 408.8 | Upgrade
|
Current Portion of Leases | 34.8 | 32 | - | - | - | - | Upgrade
|
Current Income Taxes Payable | - | 24.4 | 9 | - | - | - | Upgrade
|
Current Unearned Revenue | - | - | - | 62.7 | 34.6 | 30.6 | Upgrade
|
Other Current Liabilities | 2.2 | 3.9 | 20.7 | 20 | 17.8 | 15.2 | Upgrade
|
Total Current Liabilities | 429.7 | 654.8 | 537.7 | 245.8 | 186.5 | 565.3 | Upgrade
|
Long-Term Debt | - | - | - | 335.1 | 317.9 | - | Upgrade
|
Long-Term Leases | 251.4 | 258.3 | 93.5 | 105.3 | 94.4 | 86.7 | Upgrade
|
Other Long-Term Liabilities | 135 | 106.3 | 29.7 | 12.3 | 9.7 | 17.1 | Upgrade
|
Total Liabilities | 816.1 | 1,019 | 660.9 | 698.5 | 608.5 | 669.1 | Upgrade
|
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | Upgrade
|
Additional Paid-In Capital | 2,623 | 2,382 | 2,122 | 2,011 | 1,850 | 1,768 | Upgrade
|
Retained Earnings | 81.1 | -157.1 | -406.8 | -635.8 | -725.4 | -1,133 | Upgrade
|
Comprehensive Income & Other | 14.5 | 7 | -7.9 | -1.7 | 1.8 | 1.4 | Upgrade
|
Shareholders' Equity | 2,719 | 2,232 | 1,708 | 1,374 | 1,126 | 636.9 | Upgrade
|
Total Liabilities & Equity | 3,535 | 3,251 | 2,369 | 2,073 | 1,735 | 1,306 | Upgrade
|
Total Debt | 286.2 | 460.4 | 262.9 | 440.4 | 412.3 | 495.5 | Upgrade
|
Net Cash (Debt) | 941.8 | 571.2 | 726.4 | 270.9 | 388.7 | 175 | Upgrade
|
Net Cash Growth | 14.64% | -21.37% | 168.14% | -30.31% | 122.11% | -63.42% | Upgrade
|
Net Cash Per Share | 9.10 | 5.66 | 7.34 | 2.77 | 3.97 | 1.83 | Upgrade
|
Filing Date Shares Outstanding | 101.25 | 99.51 | 96.59 | 95.24 | 93.94 | 92.29 | Upgrade
|
Total Common Shares Outstanding | 101.2 | 98.7 | 96.5 | 94.9 | 93.5 | 92.27 | Upgrade
|
Working Capital | 1,447 | 952.2 | 915.8 | 727 | 829.7 | 265.7 | Upgrade
|
Book Value Per Share | 26.87 | 22.61 | 17.70 | 14.48 | 12.04 | 6.90 | Upgrade
|
Tangible Book Value | 2,678 | 2,191 | 1,665 | 1,374 | 1,126 | 636.9 | Upgrade
|
Tangible Book Value Per Share | 26.47 | 22.20 | 17.26 | 14.48 | 12.04 | 6.90 | Upgrade
|
Machinery | - | 115.7 | 87 | 75.6 | 56.8 | 49.2 | Upgrade
|
Leasehold Improvements | - | 38.1 | 37.9 | 34.9 | 29.5 | 26.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.